20502 ⎘
Medicinal preparations containing organic active ingredients; Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS
#302ANALGESIC AGENT COMPRISING CYCLIC PHOSPHATIDIC ACID DERIVATIVE
#303COMPOUNDS HAVING LIPID LOWERING PROPERTIES
#304Use of cyclipostin derivatives for the treatment of mycobacterial infectious diseases
#305Thyromimetics for the Treatment of Fatty Liver Diseases
#306Methods of treating vasodilatory shock
#307Micelles
#308Flavonoid compounds and uses thereof
#309Multikinase inhibitors for use in the treatment of cancer
#310Phosphorylated pyrone analogs and methods
#311Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
#312Compounds Having Cytokine Modulating Properties
#313Delivery or removal of metals from biological systems
#314Method for minimizing or avoiding adverse effects of vesicants
#315Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
#316Method of short term skin wrinkles correction using strontium divalent ion
#317Reduced-odor thiol compositions
#318Process for preparation of HIV protease inhibitors
#319Method and nutraceutical composition for mammals
#320Combination of insulin and ascorbate to enhance wound healing
#321Anti-first-pass effect compounds
#322Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
#323Highly active lysophosphatidic acid and method of screening therewith
#324Stabilized ascorbic acid derivative
#325Tumor eradication by inositol-tripyrophosphate
#326Composition and use of RAR antagonists for promoting chondrogenesis
#327Wound healing compound
#328Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis
#329LPA2 receptor agonist inhibitors of CFTR
#330Phosphate derivatives of pharmaceutical products
#331Water-dispersible carotenoids, including analogs and derivatives
#332Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
#333Resistance-repellent retroviral protease inhibitors
#334Isoflavone derivatives
#335Methods and compositions for treating or preventing cancer
#336Andrographolide derivatives to treat viral infections
#337Formulations with anti-tumour action
#338Hydrous gel and production process and use of the hydrous gel
#339Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes
#340Phosphonate analogs of HIV integrase inhibitor compounds
#341Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
#342Stabilized ascorbic acid derivatives
#343Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
#344Pharmaceutical compositions comprising a NOS inhibitor
#345Compositions and methods for selectively activating human sirtuins
#346Methods for screening cellular proliferation using isotope labels
#347Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
#348Resistance-repellent retroviral protease inhibitors
#349Oxygenated dibenzo-alpha-pyrone chromoproteins
#350Composition and method to improve quality and yield of meat products
#351Methods of treating skin with diphosphonate derivatives
#352Anti-first-pass effect compounds
#353Autoinducer-2 compounds as immunomodulatory agents
#354Micelles
#355Vitamin E phosphate/phosphatidycholine liposomes to protect from or ameliorate cell damage
#356Skin care composition that mediates cell to cell communication
#357Hypoestoxides, derivatives, agonists and crude extracts thereof for use in cosmetic compositions
#358Isotopically labelled DNA
#359Compositions containing melon extracts
#360Beta-lactamase inhibitors, formulations, and uses thereof